In Silico Studies on Psilocybin Drug Derivatives Against SARS-CoV-2 and Cytokine Storm of Human Interleukin-6 Receptor.
Front Immunol
; 12: 794780, 2021.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1662581
ABSTRACT
Various metabolites identified with therapeutic mushrooms have been found from different sources and are known to have antibacterial, antiviral, and anticancer properties. Over thousands soil growth-based mushroom metabolites have been discovered, and utilized worldwide to combat malignancy. In this study, psilocybin-mushroom that contains the psychedelic compounds such as psilacetin, psilocin, and psilocybine were screened and found to be inhibitors of SARS-CoV-2 Mprotease. It has been found that psilacetin, psilocin, and psilocybine bind to Mprotease with -6.0, -5.4, and -5.8 kcal/mol, respectively. Additionally, the psilacetin was found to inhibit human interleukin-6 receptors to reduce cytokine storm. The binding of psilacetin to Mprotease of SARS-CoV-2 and human interleukin-6 receptors changes the structural dynamics and Gibbs free energy patterns of proteins. These results suggested that psilocybin-mushroom could be utilized as viable potential chemotherapeutic agents for SARS-CoV-2.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Psilocibina
/
Receptores de Interleucina-6
/
Síndrome de Liberación de Citoquinas
/
SARS-CoV-2
/
Tratamiento Farmacológico de COVID-19
Límite:
Humanos
Idioma:
Inglés
Revista:
Front Immunol
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
Fimmu.2021.794780
Similares
MEDLINE
...
LILACS
LIS